SRM Mass Spectrometry Assay for p16 Protein Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including traditional chemotherapeutic agents and targeted therapies, lack specificity in distinguishing between cancer cells and normal cells, leading to unintended harm to healthy cells, and there is a need for more precise methods to measure p16 protein levels for predictive and diagnostic purposes in cancer treatment.
Innovation Solution
A quantitative proteomics-based Selected Reaction Monitoring (SRM) assay using mass spectrometry to quantify p16 protein levels in formalin-fixed tissues, enabling the measurement of specific peptides and their modifications, which can aid in diagnosing cancer stages, predicting treatment responses, and identifying HPV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapeutic agents are used to kill rapidly dividing cells, then cancer cells are eliminated, but normal growing cells are also damaged
Solution Approach 1:
The patent changes the measurement parameter from general cell proliferation markers to specific p16 protein expression levels and phosphorylation states. By quantifying p16 protein levels and CDK4/6 pathway activation status through mass spectrometry, the treatment can be tailored to patients whose tumors depend on this pathway, sparing those whose cancers use different mechanisms and thus protecting normal cells from unnecessary toxicity.
Solution Approach 2:
The patent replaces the non-specific mechanical cell-killing mechanism of traditional chemotherapy with a precision-based approach using mass spectrometry to detect molecular signatures. This substitution enables identification of tumors with specific molecular characteristics (high p16 expression, activated CDK4/6 pathway) that respond to targeted therapies, replacing blanket chemotherapy with personalized treatment based on molecular profiling.
2Reliability
If targeted therapies are developed to attack cancer-specific proteins, then specificity to cancer cells is improved, but measurement precision of protein levels is needed for predictive purposes
Solution Approach 1:
The patent extracts and isolates specific peptide sequences from the p16 protein that contain phosphorylation sites critical for CDK4/6 pathway regulation. By focusing mass spectrometry detection on these specific phosphorylated peptides rather than total p16 protein, the method achieves precise measurement of the biologically active form of the protein, enabling accurate prediction of response to CDK4/6 inhibitors.
Solution Approach 2:
The patent applies local quality by detecting specific post-translational modifications (phosphorylation at specific amino acid residues) within the p16 protein rather than measuring overall protein abundance. This localized measurement of phosphorylation status at critical residues provides information about pathway activation state, enabling precise prediction of therapeutic response with higher accuracy than total protein levels.
3Measurement precision
If mass spectrometry-based SRM assay is used to quantify p16 protein levels, then measurement precision is improved, but assay complexity increases
Solution Approach 1:
The patent performs preliminary enrichment of p16-containing peptides from complex tissue lysates before mass spectrometry analysis. This pre-concentration and purification step, performed before the SRM assay, simplifies the subsequent detection by reducing matrix complexity and increasing the relative abundance of target peptides, thereby maintaining measurement precision while making the overall assay more manageable.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SRM assay provides accurate and precise quantification of p16 protein levels, enabling personalized medicine approaches by correlating protein expression with cancer stages and therapeutic agent effectiveness, thus improving treatment decisions for cancer patients.
Implementation Method 1
a mass spectrometry assay that quantifies p16 in formalin fixed tissues
Implementation Method 2
a quantitative proteomics-based Selected Reaction Monitoring (SRM) assay that delivers a relevant measure of p16 protein levels
Data Source
AI summary
Methods are provided for quantifying the cyclin-dependent kinase inhibitor 2A protein (p16) p16 protein directly in biological samples that have been fixed in formalin by SRM/MRM mass spectrometry. A protein sample is prepared from the biological sample using, for example, the Liquid Tissue reagents and protocol and the p16 protein is quantitated in the resulting sample by quantitating in the protein sample at least one fragment peptide from p16. Peptides can be quantitated in modified or unmodified form. An example of a modified form of a p16 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.